Publication: Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine.
| dc.contributor.author | Felgueres, María-José | |
| dc.contributor.author | Esteso, Gloria | |
| dc.contributor.author | García-Jiménez, Álvaro F | |
| dc.contributor.author | Benguría, Alberto | |
| dc.contributor.author | Vázquez, Enrique | |
| dc.contributor.author | Aguiló, Nacho | |
| dc.contributor.author | Puentes, Eugenia | |
| dc.contributor.author | Dopazo, Ana | |
| dc.contributor.author | Murillo, Ingrid | |
| dc.contributor.author | Martín, Carlos | |
| dc.contributor.author | Rodríguez, Esteban | |
| dc.contributor.author | Reyburn, Hugh T | |
| dc.contributor.author | Valés-Gómez, Mar | |
| dc.contributor.funder | Fundación La Caixa | |
| dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | |
| dc.date.accessioned | 2025-07-16T13:29:17Z | |
| dc.date.available | 2025-07-16T13:29:17Z | |
| dc.date.issued | 2025-03-28 | |
| dc.description.abstract | Infection with Mycobacterium tuberculosis (Mtb) can produce a wide spectrum of clinical manifestations, ranging from active tuberculosis (TB) to asymptomatic latent infection. Although CD4 T-cells are key immune effectors to control TB, early after infection, the innate immune response must play a role in tackling the disease. Here, we performed in-depth analyses of the acute immune response to MTBVAC, a candidate vaccine engineered from Mtb with the aim of protecting adults from pulmonary TB disease, still a major global challenge. scRNA-seq shows expansion of CD4 and cytotoxic γδ T-cells, data confirmed by flow cytometry. CD4 T-cells exhibited lower HLA-DR and higher L-selectin expression, compared to BCG-stimulation, indicating differential activation or dynamics. Importantly, MTBVAC-activated γδ T-cells had a unique cytotoxic CD16GZMB phenotype, reminiscent of effector cells found in Mtb positive individuals controlling infection. IFN-γ and TNF-α were released in cultures, while IL-17A/F were almost undetectable. | |
| dc.description.peerreviewed | Sí | |
| dc.description.tableofcontents | The group of MVG belongs to the research network Cancer hub-CSIC and to the EU-COST action IMMUNO-model. M.J.F. and A.F.G.J. were registered PhD students at the Molecular Biosciences doctoral program of the Universidad Autónoma de Madrid (UAM).This study was funded by grants RTC-2017-6379-1, PID2021-123795OB-I00 (MVG) and PID2020- 115506RB-I00 (HTR), by MICIU/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe”; Grant FPU18/01698 (AFGJ) by MICIU/AEI/10.13039/501100011033 and by “ESF Investing in your future” (ESF+); INPhINIT Doctoral Programme from La Caixa Foundation LCF/BQ/DI19/11730039 (MJF); MVG acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Program for Centres of Excellence in R&D [CEX2023-001386-S]. Funders played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript. | |
| dc.identifier.citation | NPJ Vaccines. 2025 Mar 28;10(1):58. | |
| dc.identifier.journal | NPJ Vaccines | |
| dc.identifier.pubmedID | 40155627 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/26829 | |
| dc.language.iso | eng | |
| dc.publisher | Nature Publishing Group | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/RTC-2017-6379-1 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/PID2021-123795OB-I00 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/PID2020-115506RB-I00 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/MICIU/AEI/10.13039/501100011033 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/FPU18/01698 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/MICIU/AEI/10.13039/501100011033 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/LCF/BQ/DI19/11730039 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/AEI/10.13039/501100011033 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/CEX2023-001386-S | |
| dc.relation.publisherversion | https://doi.org/10.1038/s41541-025-01110-3 | |
| dc.repisalud.institucion | CNIC | |
| dc.repisalud.orgCNIC | CNIC::Unidades técnicas::Genómica | |
| dc.rights.accessRights | open access | |
| dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 International | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.title | Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Cytolytic γδ T-cells and IFNγ-producing_NPJ Vaccines_2025.pdf
- Size:
- 3.56 MB
- Format:
- Adobe Portable Document Format


